Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
631 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 8 Glioblastoma Multiforme (GBM) Overview 9 Therapeutics Development 10 Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 12 Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 23 Glioblastoma Multiforme (GBM) - Pipeline Products Glance 26 Glioblastoma Multiforme (GBM) - Products under Development by Companies 30 Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 42 Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 45 Glioblastoma Multiforme (GBM) - Therapeutics Assessment 159 Drug Profiles 180 Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 492 Glioblastoma Multiforme (GBM) - Dormant Projects 594 Glioblastoma Multiforme (GBM) - Discontinued Products 596 Glioblastoma Multiforme (GBM) - Product Development Milestones 597 Appendix 607
List of Tables Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2014 33 Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2014 34 Number of Products under Development by Companies, H2 2014 36 Number of Products under Development by Companies, H2 2014 (Contd..1) 37 Number of Products under Development by Companies, H2 2014 (Contd..2) 38 Number of Products under Development by Companies, H2 2014 (Contd..3) 39 Number of Products under Development by Companies, H2 2014 (Contd..4) 40 Number of Products under Development by Companies, H2 2014 (Contd..5) 41 Number of Products under Development by Companies, H2 2014 (Contd..6) 42 Number of Products under Development by Companies, H2 2014 (Contd..7) 43 Number of Products under Development by Companies, H2 2014 (Contd..8) 44 Number of Products under Development by Companies, H2 2014 (Contd..9) 45 Number of Products under Investigation by Universities/Institutes, H2 2014 47 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 48 Comparative Analysis by Late Stage Development, H2 2014 49 Comparative Analysis by Clinical Stage Development, H2 2014 50 Comparative Analysis by Early Stage Development, H2 2014 51 Comparative Analysis by Unknown Stage Development, H2 2014 52 Products under Development by Companies, H2 2014 53 Products under Development by Companies, H2 2014 (Contd..1) 54 Products under Development by Companies, H2 2014 (Contd..2) 55 Products under Development by Companies, H2 2014 (Contd..3) 56 Products under Development by Companies, H2 2014 (Contd..4) 57 Products under Development by Companies, H2 2014 (Contd..5) 58 Products under Development by Companies, H2 2014 (Contd..6) 59 Products under Development by Companies, H2 2014 (Contd..7) 60 Products under Development by Companies, H2 2014 (Contd..8) 61 Products under Development by Companies, H2 2014 (Contd..9) 62 Products under Development by Companies, H2 2014 (Contd..10) 63 Products under Development by Companies, H2 2014 (Contd..11) 64 Products under Investigation by Universities/Institutes, H2 2014 65 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 66 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 67 Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2014 68 Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2014 69 Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 70 Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corporation, H2 2014 71 Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2014 72 Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2014 73 Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2014 74 Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline plc, H2 2014 75 Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H2 2014 76 Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2014 77 Glioblastoma Multiforme (GBM) - Pipeline by Nemucore Medical Innovations, Inc., H2 2014 78 Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 79 Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Corporation, H2 2014 80 Glioblastoma Multiforme (GBM) - Pipeline by Sangamo BioSciences, Inc., H2 2014 81 Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc., H2 2014 82 Glioblastoma Multiforme (GBM) - Pipeline by Celltrion, Inc., H2 2014 83 Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 84 Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2014 85 Glioblastoma Multiforme (GBM) - Pipeline by Actelion Ltd, H2 2014 86 Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc., H2 2014 87 Glioblastoma Multiforme (GBM) - Pipeline by Biocon Limited, H2 2014 88 Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2014 89 Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2014 90 Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau S.p.A., H2 2014 91 Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp., H2 2014 92 Glioblastoma Multiforme (GBM) - Pipeline by Exelixis, Inc., H2 2014 93 Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech, Inc., H2 2014 94 Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corporation, H2 2014 95 Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2014 96 Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H2 2014 97 Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 98 Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 99 Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 100 Glioblastoma Multiforme (GBM) - Pipeline by Novogen Limited, H2 2014 101 Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 102 Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corporation, H2 2014 103 Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Limited, H2 2014 104 Glioblastoma Multiforme (GBM) - Pipeline by Green Cross Cell Corporation, H2 2014 105 Glioblastoma Multiforme (GBM) - Pipeline by Panacea Biotec Limited, H2 2014 106 Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 107 Glioblastoma Multiforme (GBM) - Pipeline by Nanobiotix, H2 2014 108 Glioblastoma Multiforme (GBM) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 109 Glioblastoma Multiforme (GBM) - Pipeline by Colby Pharmaceutical Company, H2 2014 110 Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics, Inc., H2 2014 111 Glioblastoma Multiforme (GBM) - Pipeline by Fusion Antibodies Ltd, H2 2014 112 Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 113 Glioblastoma Multiforme (GBM) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 114 Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences, H2 2014 115 Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Limited, H2 2014 116 Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2014 117 Glioblastoma Multiforme (GBM) - Pipeline by immatics biotechnologies GmbH, H2 2014 118 Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2014 119 Glioblastoma Multiforme (GBM) - Pipeline by AGY Therapeutics, Inc., H2 2014 120 Glioblastoma Multiforme (GBM) - Pipeline by Cellectis S.A., H2 2014 121 Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2014 122 Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics, Inc., H2 2014 123 Glioblastoma Multiforme (GBM) - Pipeline by Ambrx, Inc., H2 2014 124 Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 125 Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 126 Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H2 2014 127 Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Therapeutics, Inc., H2 2014 128 Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2014 129 Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories, LLC, H2 2014 130 Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics, Inc., H2 2014 131 Glioblastoma Multiforme (GBM) - Pipeline by VG Life Sciences, Inc., H2 2014 132 Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2014 133 Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research, Inc., H2 2014 134 Glioblastoma Multiforme (GBM) - Pipeline by InteRNA Technologies B.V., H2 2014 135 Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx, Inc., H2 2014 136 Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical, Inc., H2 2014 137 Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc., H2 2014 138 Glioblastoma Multiforme (GBM) - Pipeline by Sirnaomics, Inc., H2 2014 139 Glioblastoma Multiforme (GBM) - Pipeline by AB Science, H2 2014 140 Glioblastoma Multiforme (GBM) - Pipeline by Oncovir, Inc., H2 2014 141 Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 142 Glioblastoma Multiforme (GBM) - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2014 143 Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc., H2 2014 144 Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics, Inc., H2 2014 145 Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma, H2 2014 146 Glioblastoma Multiforme (GBM) - Pipeline by biOasis Technologies Inc., H2 2014 147 Glioblastoma Multiforme (GBM) - Pipeline by Houston Pharmaceuticals, Inc., H2 2014 148 Glioblastoma Multiforme (GBM) - Pipeline by Advanced Cancer Therapeutics, H2 2014 149 Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine, Inc., H2 2014 150 Glioblastoma Multiforme (GBM) - Pipeline by DiscoveryBiomed, Inc., H2 2014 151 Glioblastoma Multiforme (GBM) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 152 Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014 153 Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics, Inc., H2 2014 154 Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC, Inc., H2 2014 155 Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2014 156 Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H2 2014 157 Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 158 Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co., Ltd., H2 2014 159 Glioblastoma Multiforme (GBM) - Pipeline by CytomX Therapeutics, Inc., H2 2014 160 Glioblastoma Multiforme (GBM) - Pipeline by Selvita SA, H2 2014 161 Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals, LLC., H2 2014 162 Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H2 2014 163 Glioblastoma Multiforme (GBM) - Pipeline by EntreChem, S.L., H2 2014 164 Glioblastoma Multiforme (GBM) - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 165 Glioblastoma Multiforme (GBM) - Pipeline by Oligovax SAS, H2 2014 166 Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2014 167 Glioblastoma Multiforme (GBM) - Pipeline by Sagetis Biotech, S.L., H2 2014 168 Glioblastoma Multiforme (GBM) - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2014 169 Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H2 2014 170 Glioblastoma Multiforme (GBM) - Pipeline by Panacela Labs, Inc., H2 2014 171 Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics S.L., H2 2014 172 Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical, Inc., H2 2014 173 Glioblastoma Multiforme (GBM) - Pipeline by Antoxis Limited, H2 2014 174 Glioblastoma Multiforme (GBM) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 175 Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H2 2014 176 Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H2 2014 177 Glioblastoma Multiforme (GBM) - Pipeline by Argon Pharma S.L., H2 2014 178 Glioblastoma Multiforme (GBM) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 179 Glioblastoma Multiforme (GBM) - Pipeline by AlphaMab Co., Ltd, H2 2014 180 Glioblastoma Multiforme (GBM) - Pipeline by Galileo Research s.r.l., H2 2014 181 Assessment by Monotherapy Products, H2 2014 182 Assessment by Combination Products, H2 2014 183 Number of Products by Stage and Target, H2 2014 186 Number of Products by Stage and Mechanism of Action, H2 2014 193 Number of Products by Stage and Route of Administration, H2 2014 199 Number of Products by Stage and Molecule Type, H2 2014 202 Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H2 2014 515 Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2014 617 Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2014 619
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
